Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4168013
Max Phase: Preclinical
Molecular Formula: C72H131N17O17
Molecular Weight: 1506.94
Molecule Type: Unknown
Associated Items:
ID: ALA4168013
Max Phase: Preclinical
Molecular Formula: C72H131N17O17
Molecular Weight: 1506.94
Molecule Type: Unknown
Associated Items:
Canonical SMILES: CCCC[C@@H](CC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCC)C(N)=O)NC(=O)[C@@H](CO)NC(=O)[C@@H](NC(=O)C[C@H](C)NC(=O)[C@@H](NC(=O)[C@@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)C[C@H](NC(=O)[C@@H](NC(=O)[C@H](CCCCN)NC(=O)C[C@@H]1CCCN1C(C)=O)[C@@H](C)CC)[C@@H](C)CC)C(C)C)[C@@H](C)CC
Standard InChI: InChI=1S/C72H131N17O17/c1-13-18-25-47(36-58(95)79-50(28-20-22-32-73)65(99)82-49(64(76)98)27-19-14-2)78-68(102)54(39-90)85-71(105)62(43(9)16-4)86-57(94)35-45(11)77-70(104)61(41(6)7)87-69(103)55(40-91)84-66(100)52(30-31-56(75)93)81-60(97)38-53(42(8)15-3)83-72(106)63(44(10)17-5)88-67(101)51(29-21-23-33-74)80-59(96)37-48-26-24-34-89(48)46(12)92/h41-45,47-55,61-63,90-91H,13-40,73-74H2,1-12H3,(H2,75,93)(H2,76,98)(H,77,104)(H,78,102)(H,79,95)(H,80,96)(H,81,97)(H,82,99)(H,83,106)(H,84,100)(H,85,105)(H,86,94)(H,87,103)(H,88,101)/t42-,43-,44-,45-,47-,48-,49-,50-,51-,52-,53-,54+,55+,61-,62-,63-/m0/s1
Standard InChI Key: SFFQDJXAJFFFOH-QSJQWNKCSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Unknown | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1506.94 | Molecular Weight (Monoisotopic): 1505.9909 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. de Lucio H, Gamo AM, Ruiz-Santaquiteria M, de Castro S, Sánchez-Murcia PA, Toro MA, Gutiérrez KJ, Gago F, Jiménez-Ruiz A, Camarasa MJ, Velázquez S.. (2017) Improved proteolytic stability and potent activity against Leishmania infantum trypanothione reductase of α/β-peptide foldamers conjugated to cell-penetrating peptides., 140 [PMID:29017116] [10.1016/j.ejmech.2017.09.032] |
Source(1):